Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease (ESRD) and is therefore a major burden on the healthcare system. Patients with DKD are highly susceptible to developing cardiovascular disease, which contributes to increased morbidity and mortality rates. While progress has been made to inhibit the acceleration of DKD, current standards of care reduce but do not eliminate the risk of DKD. There is growing appreciation for the role of inflammation in modulating the process of DKD. The focus of this review is on providing an overview of the current status of knowledge regarding the pathologic roles of inflammation in the development of DKD. Finally, we summarize recent therapeutic advances to prevent DKD, with a focus on the anti-inflammatory effects of newly developed agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Importantly, this trial showed no imbalance in rates of amputation or bone fracture, and no new safety concerns were identified [53].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 1×
“For example, the renal composite outcomes (doubling of creatinine, renal replacement therapy, or renal death) decreased by 46% in patients with type 2 diabetes treated with empagliflozin [52].”
BackgroundNrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“reported that Nrf2 binds to the regulatory regions of inflammatory genes and thereby induces their transcription in macrophages and alleviates RNA polymerase II recruitment [37].”
BackgroundAdler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890 · cited 1×
“Bardoxolone methyl, one such Nrf2 activator, has been demonstrated in clinical trials to have reno-protective effects in patients with type 2 diabetes [40].”
BackgroundTranscriptome Analysis of Human Diabetic Kidney Disease
Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011) · Diabetes · doi:10.2337/db10-1181 · Cited by 642
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Cited by
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
Tanase, D. M., Gosav, E. M., Anton, M. I., Floria, M., Seritean Isac, P. N., Hurjui, L. L., Tarniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezus, C. (2022) · Biomolecules · doi:10.3390/biom12091227 · Cited by 198
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Lee, J., Yun, J., & Ko, S. (2022) · Nutrients · doi:10.3390/nu14153086 · Cited by 181
Chen, S., Lv, L., Liu, B., & Tang, R. (2020) · Cell Proliferation · doi:10.1111/cpr.12763 · Cited by 158
Zhang, Y., Le, X., Zheng, S., Zhang, K., He, J., Liu, M., Tu, C., Rao, W., Du, H., Ouyang, Y., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02855-7 · Cited by 148
Thomas, H. Y., & Versypt, A. N. F. (2022) · Journal of Biological Engineering · doi:10.1186/s13036-022-00299-4 · Cited by 135
Xu, J., Kitada, M., Ogura, Y., Liu, H., & Koya, D. (2021) · Cells · doi:10.3390/cells10061457 · Cited by 131
Liu, X., Hu, X., Yang, H., Gui, L.-M., Cai, Z.-X., Qi, M.-S., & Dai, C. (2022) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x22500744 · Cited by 131
Chaudhuri, A., Ghanim, H., & Arora, P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14601 · Cited by 120
“growth factor, osteopontin).(17,26) Activation of pro-inflammatory pathways in the presence of elevated intracellular ROS causes epigenetic changes and the expression of pro-inflammatory genes that persist after glycaemia is normalized.”
BackgroundLiu, J., Zhang, Y., Sheng, H., Liang, C.-L., Liu, H., Moran-Guerrero, J. A., Lu, Z., Mao, W., Dai, Z., Liu, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733808 · Cited by 118
Song, C., Wang, S., Fu, Z., Chi, K., Geng, X., Liu, C., Cai, G., Chen, X., Wu, D., & Hong, Q. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04803-y · Cited by 112
Wang, Z., Wang, Z., Huang, W., 索吉明, Chen, X., Ding, K., Sun, Q., & Zhang, H. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.213 · Cited by 109
Mechanisms of diabetic kidney disease and established and emerging treatments
Leon, V. M., Hilburg, R., & Suszták, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01171-3 · Cited by 127
Zheng, W., Guo, J., & Liu, Z. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01079-5 · Cited by 113
Accelerated Kidney Aging in Diabetes Mellitus
Guo, J., Zheng, H. J., Zhang, W., Lou, W., Xia, C., Han, X. T., Huang, W. J., Zhang, F., Wang, Y., & Liu, W. J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1234059 · Cited by 93
Li, X., Wang, L., Liu, M., Zhou, H., & Xu, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1285509 · Cited by 107
Porcine models for studying complications and organ crosstalk in diabetes mellitus
Renner, S., Blutke, A., Clauß, S., Deeg, C. A., Kemter, E., Merkus, D., Wanke, R., & Wolf, E. (2020) · Cell and Tissue Research · doi:10.1007/s00441-019-03158-9 · Cited by 106
Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression
Khan, S., Gaivin, R. J., Abramovich, C. M., Boylan, M. O., Calles, J., & Schelling, J. R. (2020) · JCI Insight · doi:10.1172/jci.insight.136845 · Cited by 90
Sahakyan, G., Véjux, A., & Sahakyan, N. Z. (2022) · Molecules · doi:10.3390/molecules27249035 · Cited by 87
AIF1: Function and Connection with Inflammatory Diseases
de Leon-Oliva, D., García-Montero, C., Fraile-Martínez, Ó., Boaru, D. L., García-Puente, L., Rios-Parra, A., Garrido-Gil, M. J., Casanova-Martín, C., García-Honduvilla, N., Buján, J., et al. (2023) · Biology · doi:10.3390/biology12050694 · Cited by 77
Significance of Metformin Use in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., & Tanabe, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124239 · Cited by 74
Self-citationRam, C., Jha, A. K., Ghosh, A., Gairola, S., Syed, A. M., Murty, U. S., Naidu, V. G. M., & Sahu, B. D. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173503 · Cited by 65
Li, N., Zhao, T., Cao, Y., Zhang, H., Peng, L., Wang, Y., Zhou, X., Wang, Q., Li, J., Yan, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.623489 · Cited by 66
Renoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 66
Self-citationHofherr, A., Williams, J. H., Gan, L., Söderberg, M. P., Hansen, P., & Woollard, K. J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02794-8 · Cited by 62
Zabad, O. M., Samra, Y. A., & Eissa, L. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116965 · Cited by 62
Liu, W., Chen, X., Wang, Y., Chen, Y., Chen, S., Gong, W., Chen, T., Sun, L., Zheng, C., Yin, B., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104506 · Cited by 66
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Dare, A., Channa, M. L., & Nadar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111921 · Cited by 65
Targeting Redox Imbalance as an Approach for Diabetic Kidney Disease
Matoba, K., Takeda, Y., Nagai, Y., Yokota, T., Utsunomiya, K., & Nishimura, R. (2020) · Biomedicines · doi:10.3390/biomedicines8020040 · Cited by 62
Self-citationCecerska‐Heryć, E., Engwert, W., Michałów, J., Marciniak, J., Birger, R., Serwin, N. M., Heryć, R., Polikowska, A., Goszka, M., Wojciuk, B., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05818-z · Cited by 66
Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
Gu, Y.-Y., Lu, F., Huang, X., Zhang, L., Mao, W., Yu, X., Liu, X., & Lan, H.-Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583528 · Cited by 57
Chen, J., Zhang, Q., Guo, J., Gu, D., Liu, J., Luo, P., Bai, Y., Chen, J., Zhang, X., Nie, S., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.003 · Cited by 57
Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy
Lv, J., Wu, Y. Z., Mai, Y., & Bu, S. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3960857 · Cited by 56
Shi, J., Li, R., Yang, S., Phang, Y. L., Zheng, C., & Zhang, H. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8205983 · Cited by 50
Zheng, W., Guo, J., Lu, X., Qiao, Y., Liu, D., Pan, S., Liang, L., Liu, C., Zhu, H., Liu, Z., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155155 · Cited by 53
Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
Sheng, L., Bayliss, G. P., & Zhuang, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.598910 · Cited by 46
Roles of SIRT6 in kidney disease: a novel therapeutic target
Yang, X., Feng, J., Liang, W., Zhu, Z., Chen, Z., Hu, J., Yang, D., & Ding, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04061-9 · Cited by 48
Mizuno, Y., Yamamotoya, T., Nakatsu, Y., Ueda, K., Matsunaga, Y., Inoue, M., Sakoda, H., Fujishiro, M., Ono, H., Kikuchi, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194680 · Cited by 44
Wang, J., Tao, Y., Zhao, F., Liu, T., Shen, X., & Zhou, L. (2023) · Renal Failure · doi:10.1080/0886022x.2022.2121929 · Cited by 42
Tao, M., Zheng, D., Liang, X., Wu, D., Hu, K., Jin, J., & He, Q. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12231 · Cited by 41
RetractedHao, J., Xiaotian, L., Tang, J., Xueying, C., Honge, J., Bo, Z., Hao, L., & Zhang, L. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1668000 · Cited by 43
Li, L., Shen, Q., & Rao, S. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s393135 · Cited by 49
Fisiopatología y alteraciones clínicas de la diabetes mellitus tipo 2: revisión de literatura
Fernández, C. I. J., Pereira, Y. A. M., Chang, A. S. O., Olmedo, S. I. G., & Gaete, M. C. A. (2022) · Nova · doi:10.22490/24629448.6184 · Cited by 66
Bruceine A protects against diabetic kidney disease via inhibiting galectin-1
Li, H., Zhao, X., Zheng, L., Wang, X., Lin, S., Shen, J., Ren, H., Li, Y., Qiu, Q., & Wang, Z. (2022) · Kidney International · doi:10.1016/j.kint.2022.04.020 · Cited by 39
The role of mitochondrial dysfunction in kidney injury and disease
Jia, X., Zhu, L., Zhu, Q., & Zhang, J. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103576 · Cited by 37
Increased serum asprosin is correlated with diabetic nephropathy
Wang, R., Lin, P., Sun, H., & Hu, W. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00668-x · Cited by 38
Maresin 1 Alleviates Diabetic Kidney Disease via LGR6‐Mediated cAMP‐SOD2‐ROS Pathway
Li, X., Xu, B.-T., Wu, J. T., Pu, Y., Wan, S., Zeng, Y., Wang, M., Luo, L., Zhang, F., Jiang, Z., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7177889 · Cited by 36
Influence of exercise training on diabetic kidney disease: A brief physiological approach
Amaral, L. S. D. B., Souza, C. S., Lima, H. N., & Soares, T. D. J. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220928986 · Cited by 40
Matoba, K., Takeda, Y., Nagai, Y., Sekiguchi, K., Yokota, T., Utsunomiya, K., & Nishimura, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585633 · Cited by 34
Self-citationDevelopment of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy
Maiti, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189985 · Cited by 33
Yang, Y., Tan, H.-B., Zhang, X., Zhang, Y., Lin, Q., Huang, M., Lin, Z., Mo, J.-Z., Zhang, Y., Lan, T., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115165 · Cited by 31
Su, X., Guo, H., Zhou, Y., Cao, A., Shen, Q., Zhu, B., Yao, X., Wang, Y., Wang, H., & Wang, L. (2023) · Phytotherapy Research · doi:10.1002/ptr.7875 · Cited by 38
The Role of Iron and Nerve Inflammation in Diabetes Mellitus Type 2-Induced Peripheral Neuropathy
Paeschke, S., Baum, P., Toyka, K. V., Blüher, M., Koj, S., Klöting, N., Bechmann, I., Thiery, J., Kosacka, J., & Nowicki, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.005 · Cited by 32
Epigenetic Histone Modifications in the Pathogenesis of Diabetic Kidney Disease
Lu, H., Dai, W., & He, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s288500 · Cited by 31
TGF-β: elusive target in diabetic kidney disease
Rani, P., Laxminarayana, S. L. K., Swaminathan, S. M., Nagaraju, S. P., Bhojaraja, M. V., Shetty, S., & Kanakalakshmi, S. T. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2483990 · Cited by 30
Li, G., Zhang, J., Liu, D., Wei, Q., Wang, H., Lv, Y., Ye, Z., Liu, G., & Li, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767654 · Cited by 30
Emerging Role of LncRNA Regulation for NLRP3 Inflammasome in Diabetes Complications
Lü, X., Tan, Q., Ma, J., Zhang, J., & Yu, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.792401 · Cited by 35
Ferroptosis: a new strategy for Chinese herbal medicine treatment of diabetic nephropathy
Wei, M., Liu, X., Tan, Z., Tian, X., Li, M., & Wei, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1188003 · Cited by 28
Total flavonoids of Astragalus protects glomerular filtration barrier in diabetic kidney disease
Liu, P., Hong, K.-F., Liu, Y.-D., Sun, Z.-Y., Zhao, T., Li, X., Lao, C.-C., Tan, S.-F., Zhang, H.-Y., Zhao, Y., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00903-3 · Cited by 29
Hughes, E. P., Wang, X. X., Sabol, L., Barton, K., Hegde, S., Myakala, K., Krawczyk, E., Rosenberg, A. Z., & Levi, M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00110.2025 · Cited by 29
Liu, W., Zheng, S., & Du, X. (2024) · PubMed Central · doi:10.2147/dmso.s447026 · Cited by 38
Ma, Y., Deng, Y., Li, N., Dong, A., Li, H., Chen, S., Zhang, S., & Zhang, M. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115768 · Cited by 29
Li, M.-Y., Duan, J., Wang, X., Liu, M., Yang, Q.-Y., Li, Y., Cheng, K., Liu, H.-Q., & Wang, F. (2023) · ACS Omega · doi:10.1021/acsomega.3c03055 · Cited by 26
Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients
Li, B., Tian, X., Guo, S., Zhang, M., Li, J., Zhai, N., Wang, H., & Zhang, Y. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02568-x · Cited by 26
Retinal microvascular signs and risk of diabetic kidney disease in asian and white populations
Nusinovici, S., Sabanayagam, C., Lee, K. E., Zhang, L., Cheung, C. Y.-L., Tai, E. S., Tan, G. S. W., Cheng, C., Klein, B. E. K., & Wong, T. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-84464-7 · Cited by 27
Jin, D., Zhang, Y., Zhang, Y., Duan, L., Zhou, R., Duan, Y., Sun, Y., Lian, F., & Tong, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.734151 · Cited by 32
SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease
Júnior, P. A. B. M., Lass, A. D., Pilger, B. I., Fornazari, R., de Moraes, T. P., & Pinho, R. A. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0187en · Cited by 33
The implications of histamine metabolism and signaling in renal function
Sudarikova, A. V., Fomin, M. V., Yankelevich, I. A., & Ilatovskaya, D. V. (2021) · Physiological Reports · doi:10.14814/phy2.14845 · Cited by 24
Chen, X., Zhang, H., Yang, F., Liu, Y., & Chen, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.637480 · Cited by 28
Fu, S., Cheng, Y., Wang, X., Huang, J., Su, S., Wu, H., Yu, J., & Xu, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.918657 · Cited by 30
Therapeutic efficacy of dapagliflozin on diabetic kidney disease in rats
Yang, H., Mei, Z., Chen, W., Pan, Y., Liu, L., Zhao, R., Ni, W., Wang, Y., & Fei, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109272 · Cited by 28
Kidney Inflammation, Injury and Regeneration
Baer, P. C., Koch, B., & Geiger, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031164 · Cited by 22
Wang, D., Li, Y., Dai, L., Wang, Y., Zhao, C., Wang, W., Zhang, Y., Zhao, Y., & Yu, T. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11576 · Cited by 22
ALTAMIMI, J. Z., AlFaris, N. A., Alshammari, G. M., Alagal, R. I., ALJABRYN, D. H., & Yahya, M. A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101817 · Cited by 24
Fang, Y., Wang, B., Pang, B., Zhou, Z., Xing, Y., Pang, P., Zheng, D., Zhang, G., & Yang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-53567-2 · Cited by 21
Opazo-Ríos, L., Plaza, A., Matus, Y. S., Bernal, S., Lopez‐Sanz, L., Jiménez-Castilla, L., Carpio, D., Droguett, A., Mezzano, S. A., Egido, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124225 · Cited by 21
Importance of Identifying Novel Biomarkers of Microvascular Damage in Type 1 Diabetes
Marcovecchio, M. L. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00483-6 · Cited by 20
Pharmacological action of Hedysarum polysaccharides: a review
Gao, X., Ren, C., Li, L., Zhao, H., Liu, K., Zhuang, M., Lv, X., Zhi, X., Jiang, H., Chen, Q., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1119224 · Cited by 21
Implications of the cGAS-STING pathway in diabetes: Risk factors and therapeutic strategies
Mohammadi, S., & Khorasani, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134210 · Cited by 22
Sinha, S. K., Carpio, M. B., & Nicholas, S. B. (2024) · Biomedicines · doi:10.3390/biomedicines12102209 · Cited by 21
Li, R., Yan, X., Zhao, Y., Liu, H., Song, J., Yuan, Y., Li, Q., & Su, J. (2025) · Antioxidants · doi:10.3390/antiox14030267 · Cited by 24
Lee, M., Park, H. S., Choi, M. Y., Kim, H. Z., Moon, S. J., Ha, J. Y., Choi, A. R., Park, Y. W., Park, J. S., Shin, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051394 · Cited by 20
Wang, Q. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1789880 · Cited by 19
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey, D. J. (2020) · Kidney360 · doi:10.34067/kid.0001252019 · Cited by 19
Xu, Q., Li, B., Wang, Y., Wang, C., Feng, S., Xue, L., Chen, J., & Jiang, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.651690 · Cited by 18
Liao, P.-Y., Lo, H., Liu, I.-C., Lo, L.-C., Hsiang, C., & Ho, T. (2022) · Food & Function · doi:10.1039/d1fo02788c · Cited by 19
Duan, J., He, L., Deng, W., Lu, M., Zhai, Y., Pei, F., Liu, S., & Zhang, C. (2022) · Environmental Toxicology · doi:10.1002/tox.23653 · Cited by 18
Neumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 18
Feng, B., Yang, F., Liu, J., Sun, Q., Meng, R., & Zhu, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108409 · Cited by 19
Quan, K. Y., Yap, C. G., Jahan, N. K., & Pillai, N. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109122 · Cited by 18
Xiao, M., Bai, S., Chen, J., Li, Y., Zhang, S., & Hu, Z. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00725-5 · Cited by 16
The ubiquitination of CKIP-1 mediated by Src aggravates diabetic renal fibrosis (original article)
Yang, Y., Xiao, H., Lin, Z., Chen, R., Li, S., Li, C., Sun, X., Hei, Z., Gong, W., & Huang, H. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115339 · Cited by 16
Eid, S., Hinder, L. M., Zhang, H., Eksi, R., Nair, V., Eddy, S. F., Eichinger, F. H., Park, M., Saha, J., Berthier, C. C., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002387r · Cited by 19
Ndevahoma, F., Nkambule, B. B., Dludla, P. V., Mukesi, M., Natanael, K. N., & Nyambuya, T. M. (2021) · eJHaem · doi:10.1002/jha2.257 · Cited by 14
Vitamin B6 and diabetes and its role in counteracting advanced glycation end products
Vernì, F. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.02.005 · Cited by 16
Ino, J., Kasama, E., Kodama, M., Sato, K., Eizumi, H., Kawashima, Y., Sekiguchi, M., Fujiwara, T., Yamazaki, A., Suzuki, C., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.4927-20 · Cited by 16
Metadata
- Authors
- Matoba, K., Takeda, Y., Nagai, Y., Kawanami, D., Utsunomiya, K., & Nishimura, R.
- Affiliations
- Jikei University School of Medicine (JP)
- Fukuoka University (JP)
- Corresponding author
- Matoba, Keiichiro
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-07-10
- Volume
- 20
- Issue
- 14
- Pages
- 3393
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6678414
- OpenAlex
- W2958949191
- Semantic Scholar
- 1919f7691771fef371eec317a2f8802ae08a78f7
- Cited by
- 223
- References
- 84
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 40 · 2023: 26 · 2022: 44 · 2021: 36 · 2020: 22 · 2019: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (18K15985)
- Ichiro Kanehara Foundation (N/A)
- MSD Life Science Foundation (N/A)
- Yokoyama Foundation for Clinical Pharmacology (N/A)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- diabetic nephropathy, inflammation, pathogenesis, end-stage renal disease, cardiovascular disease, anti-inflammatory therapy, novel therapeutic agents
- MeSH terms
- Animals, Diabetic Nephropathies, Disease Susceptibility, Humans, Inflammation, Signal Transduction, Biomarkers, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.